Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Clinical Trial Evaluates Liquid Biopsy for Early-Stage Breast Cancer Detection

By LabMedica International staff writers
Posted on 20 Oct 2026

Breast cancer screening relies primarily on mammography, but abnormal findings can lead to additional imaging, biopsy, or repeat imaging after six months, creating anxiety and potentially delaying treatment when cancer is ultimately diagnosed. More...

More than 300,000 women in the U.S. are diagnosed with breast cancer each year, highlighting the need for tools that can provide earlier diagnostic clarity. In response to this need, researchers have launched a clinical trial to evaluate whether a blood test can help detect breast cancer as early as Stage I.

USC Norris Comprehensive Cancer Center (Los Angeles, CA, USA), part of Keck Medicine of USC, has launched a phase 1 clinical trial to evaluate a liquid biopsy for early breast cancer detection. The test is being studied as an adjunct to mammography, not as a replacement for mammograms or breast biopsies. It was developed at the USC Michelson Center Convergent Science Institute in Cancer.

The liquid biopsy is designed to identify rare cancer-associated cells and tumor-associated large extracellular vesicles in blood. These extracellular vesicles are described as small particles released by cancer cells that can enter the bloodstream early in disease onset. Unlike many existing liquid biopsy approaches that focus on small pieces of DNA released by cancer cells, this method also examines cellular and extracellular-vesicle signals that early data suggest may be detectable at the earliest stages of breast cancer.

In the trial, researchers will collect two blood samples one year apart and compare test results with patients’ diagnoses to evaluate accuracy. The study will assess whether the blood test can provide additional information during breast cancer screening and help identify molecular and cellular signs of early-stage disease. Researchers are also evaluating whether the approach could support screening access for women who face barriers to mammography or who have undergone mastectomy.

The liquid biopsy method can identify several common breast cancer-associated rare-cell and extracellular-vesicle signals in the blood. The same technology could potentially be used in the future to screen for other solid tumor, including lung and colon cancer. If the phase 1 trial results are positive, researchers plan a larger phase 2 trial involving a broader patient group.

“Our hope is to determine whether this test can provide more information about breast cancer screening and detection, particularly during the stages of the disease when it may be easier to treat,” said Anastasia Martynova, MD, breast cancer specialist and medical oncologist with USC Norris and principal investigator of the trial. 

“If the test is shown to be effective, it could offer an additional screening option for women who face barriers to mammography, such as those who live in remote areas where access to screening services is limited. It could also have potential applications for women who have undergone a mastectomy, for whom mammograms are no longer an option,” said Amanda M. Woodworth, MD, director of breast health at Keck Medicine and Henry Mayo Newhall Hospital in Santa Clarita, and co-investigator of the trial.

Related Links
USC Norris Comprehensive Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.